Digital vision screening platform aims to reduce vision

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) — Retina Technologies, Inc. (“RetTech”) is advancing the development of OcuVue™, an affordable digital vision screening platform with embedded machine learning. Studies show that in the United States alone, more than 180,000 new cases of undiagnosed vision loss and blindness are discovered each year, and more than 80% of those people would still have their vision with early detection and treatment. currently available. RetTech aims to bring GPs and eye care specialists closer together through a fully integrated digital vision screening platform.

RetTech was founded by a team of medical students from the Icahn School of Medicine at Mount Sinai in New York, NY, who encountered many patients with undiagnosed vision loss and blindness while volunteering in clinics in underserved communities. RetTech is working closely with New York Eye and Ear Infirmary (NYEE), part of Mount Sinai Health System, to advance the development of OcuVue.

This sparked the development of OcuVue™, a modular vision screening solution with built-in machine learning to help healthcare providers perform early detection and provide guided referrals. Its design is lightweight and portable and can be used remotely or fully integrated into any physician’s workflow. OcuVue™ has the potential to improve the quality of vision testing in primary care and, through early detection, gives vision specialists a much better chance of successfully treating eye disease and preventing vision loss.

“We are in the midst of a revolution in digital healthcare where digital and medical technologies are rapidly merging with the goal of improving outcomes for more patients,” said Dr. James Tsai, NYEE President and Chairman of the Mount Sinai Department of Ophthalmology. “I think the ability to get regular vision screening for early detection would be a big win-win for doctors and patients alike.”

OcuVue™ is unique in its modularity, expandability and ease of use virtually anywhere. This modularity allows patients to get fast, comprehensive vision screening and retinal imaging exams in 15 minutes, eliminating the tedious need to travel between multiple machines and exam rooms, and can provide interpretations and referrals to doctors in seconds.

“We are excited to work with Retina Technologies to advance the development of OcuVue™ and the potential to expand vision diagnostics into new markets,” said Dr. Tsai.

Currently, RetTech is working on the delivery of Virtual Reality (VR) module for visual function examinations and Retinal Imaging module for early detection of retinal abnormalities. The company has worked with leading ophthalmologists and oculoplastic surgeons to complete two clinical trials for six virtual reality accelerated functional vision tests that are essential for comprehensive in-office exams. The validation of these vision tests emphasizes the potential of OcuVue™ in enabling faster and more rigorous testing in time-sensitive settings such as primary care.

“We believe we are at a critical inflection point in the adoption curve and growth of integrated digital medical devices,” said Randy Serafini, CEO of RetTech. “To successfully develop, deploy and support these types of devices requires hybrid organizations with both deep medical expertise and experience in complex digital technologies and IT integration,” he continues. “Our team has over 60 years of providing cutting-edge technology solutions, and through our relationship with Mount Sinai, we have ophthalmic expertise and experience of considerable depth and breadth.”

To ensure deployment in generalist facilities and broader physician workflows, and to develop reimbursement strategies for OcuVue™, we brought on Sumeet Murarka, MBA, as Chief Technology Officer, continues Mr. Serafini. “He has decades of experience integrating cutting-edge technologies into physician workflows throughout his tenure as CIO and CTO of New York’s largest private physician group.”

OcuVue™ is based on technologies developed at Mount Sinai and licensed to Retina Technologies. Mount Sinai has a financial interest in Retina Technologies.

RetTech is currently crowdfunding on StartEngine:

For more information, email: [email protected], or visit:, Facebook, LinkedIn, Twitter.

Related Images

Image 1: Retina Technologies OcuVue™

Demonstration of the OcuVue™ virtual reality module prototype in a primary care setting

This content was posted through the press release distribution service on

  • Retina Technologies OcuVue™

Comments are closed.